Robert James Wills, Director at CymaBay Therapeutics, Inc. (CBAY), bought 5,000 shares at $6.84 ($34K) on 2017-08-01, disclosed to the SEC on 2017-08-02.
Open-market purchase of $34k CBAY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.83 | 200 | $1K | 4.0% |
| 2 | $6.84 | 300 | $2K | 6.0% |
| 3 | $6.84 | 1,000 | $7K | 20.0% |
| 4 | $6.85 | 3,500 | $24K | 70.0% |
| Total | $6.85 avg | 5,000 | $34K | 100% |
| Filing → |
| ONCT | BUY | 2024-04-10 | $28K | — | Filing → |
| ONCT | BUY | 2024-04-01 | $117K | — | Filing → |
| ONCT | SELL | 2024-02-27 | $9K | — | Filing → |